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Dhong-Jin Kim,4 Ilene Brill,4 Jareen Meinzen-Derr,5 Amanda Tichacek,6 and Susan A. Allen6
for the Rwanda Zambia HIV Research Group
Abstract
We assessed the utility of the modified Kigali combined (MKC) staging system for predicting survival in HIV-
infected Zambian adults in a prospective, longitudinal, open cohort. From 1995 to 2004, HIV-discordant cou-
ples (one HIV-infected partner and one HIV-negative partner) were recruited from couples’ voluntary coun-
seling and testing centers in Lusaka, Zambia and followed at 3-month intervals. MKC stage, which incorporates
clinical stage with erythrocyte sedimentation rate (ESR), hematocrit, and body mass index (BMI), was deter-
mined at enrollment. Kaplan–Meier survival and Cox proportional hazard methods were used to calculate me-
dian survival and relative hazards. We enrolled 1479 HIV-discordant couples with a combined 7305 person-
years of follow-up. Among HIV-infected participants over the 9-year study period, there were 333 confirmed
deaths. The time to 50% mortality was 8.5 years with MKC stage 1 and 2 disease compared to 3.7 years with
MKC stage 4 disease at enrollment. Survival rates at 3 years were 85% with MKC stage 1 and 2 disease, 74%
with MKC stage 3 disease, and 51% with MKC stage 4 disease. A total of 275 HIV-negative partners serocon-
verted during follow-up. In comparison, survival rates at 3 years were 94% for HIV-negative participants and
92% for participants who seroconverted during follow-up. In multivariate analysis, MKC stage 4 disease (HR 
3.7, 95% CI  2.7–5.0) remained a strong predictor of mortality. Incorporating ESR, hematocrit, and BMI with
clinical staging is a powerful, low-cost tool to identify HIV-infected adults at high risk for mortality.
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Introduction
ZAMBIA HAS A SEVERE HIV-1 EPIDEMIC, like much of South-ern Africa, with an estimated HIV-1 prevalence rate of
16.5% in the general population.1 Large seroconverter cohort
studies in Europe, North America, and Australia have
proven essential in understanding the natural history of
HIV-1 disease in high-income countries and planning health-
care resources.2,3 Despite the devastating impact of HIV in
Southern Africa, few studies have evaluated the natural his-
tory of disease progression4–6 and cofactors7,8 influencing
survival in HIV-infected adults in this setting. WHO clinical
staging, however, has been demonstrated to be an impor-
tant, independent predictor of mortality,9–13 even in the era
of highly active antiretroviral therapy (HAART).14,15 The
modified Kigali combined (MKC) staging system was de-
veloped as a stronger predictor of mortality than WHO clin-
ical staging alone in Rwandan women.16 MKC staging com-
bines a clinical staging system that is similar to WHO clini-
cal staging but incorporates additional data, including body
mass index (BMI), hematocrit, and erythrocyte sedimenta-
tion rate (ESR; a marker of systemic inflammation) (see Ap-
pendix 1 for full details). Although MKC staging has not
been validated in other settings, BMI,14,15 hematocrit,15 and
C-reactive protein (another marker of systemic inflamma-
tion)17,18 have all been demonstrated to be strong predictors
of mortality in the era of HAART and improved access to
CD4 cell count testing. To evaluate whether MKC staging re-
mains a strong predictor of mortality in other settings in
Africa, we performed a mortality analysis in a large prospec-
tive, community-based cohort of HIV-discordant couples in
Zambia.
1Emory University, Division of Infectious Diseases, Atlanta, Georgia 30030.
2University Teaching Hospital, Lusaka, Zambia
3Zambia-Emory HIV Research Project, Lusaka, Zambia
4University of Alabama at Birmingham, Birmingham, Alabama 35294.
5Children’s Hospital Medical Center, Center for Epidemiology and Biostatistics, Cincinnati, Ohio 45229.
6Emory University, Rollins School of Public Health, Department of Global Health, Atlanta, Georgia 30030.
Materials and Methods
The Zambia Emory HIV Research Project (ZEHRP), in col-
laboration with the Zambian Ministry of Health, established
couples voluntary counseling and testing (CVCT) centers in
urban districts of Lusaka, a capital city with a population of
1.7 million, beginning in 1995. Details of CVCT methods and
participant recruitment have been previously described.19–21
In brief, after providing informed consent HIV serostatus
was determined with the rapid Dipstick HIV 12 antibody
screening assay (MacDonald Scientific Ltd, Harare, Zim-
babwe) and confirmed with the Capillus HIV-1/2 latex ag-
glutination test (Cambridge Biotech Ltd, Galway, Ireland).
From 1995 to 2004 over 18,000 couples received HIV testing
at CVCT centers. Approximately 33% of all HIV test results
were positive and 20% of all couples had discordant HIV test
results (one partner was HIV infected and the other partner
was HIV negative). Couples with discordant HIV test results
were invited to join a prospective cohort study on methods
to reduce rates of heterosexual HIV transmission. All dis-
cordant couples were extensively educated about their high
risk of HIV transmission and interventions to minimize this
risk. Couples were excluded from the cohort if they did not
primarily reside in Lusaka, were judged to be mentally in-
competent to provide informed consent, or if the female part-
ner was greater than 48 years old and/or the male partner
was greater than 65 years old.
All couples who enrolled in the prospective cohort study
completed a baseline demographic and past medical history
evaluation, physical examination, and laboratory testing for
ESR, hematocrit, and total lymphocyte count. Couples re-
turned at 3 month intervals to complete an interval medical
history, physical examination, and laboratory testing for ESR
and hematocrit. Seronegative partners had HIV testing re-
peated at each visit. If a couple did not return for their 3-
month study visit, a community worker was sent to their
home to determine the reason. The clinic provided free out-
patient medical care to all participants and the study phar-
macy maintained medications recommended by the WHO
essential drug list. An insurance policy was provided for hos-
pitalization and specialty outpatient care at Lusaka’s major
hospital, the University Teaching Hospital. Antiretroviral
therapy became available at government clinics in 2004, at
which point a referral system was implemented to ensure all
eligible patients received an evaluation for antiretroviral
therapy.
MKC staging combines WHO clinical staging (with mod-
ifications such as utilizing the BMI instead of weight loss and
classifying all cases of tuberculosis as clinical stage 4 disease;
see Appendix 1) with hematocrit and ESR results. Labora-
tory results are stratified as either stage A (normal) or stage
B (an abnormal hematocrit or ESR result). For HIV-infected
Zambians, an abnormal hematocrit was defined as a result
less than or equal to the sex-specific 25th percentile (male:
38%, female: 34%) and an abnormal ESR was defined as
a result greater than or equal to the sex-specific 75th per-
centile (male: 82 mm/h, female: 100 mm/h) in our co-
hort. An individual’s final MKC stage is scored from 1 to 4
based on the combined results of their modified WHO clin-
ical stage and laboratory stage as demonstrated in Fig. 1. As
part of a nested case control study to evaluate biological fac-
tors associated with an increased risk for HIV transmission,
213 (14%) HIV-infected participants had a CD4 cell count
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TABLE 1. BASELINE CHARACTERISTICS COMPARING HIV-INFECTED AND HIV-NEGATIVE ADULTS (N  2958)
HIV-infected adults HIV-negative adults
Baseline characteristics (n  1479) (n  1479) p-valuea
Female, n (%) 750 (51%) 729 (49%) 0.44
Median age, years (IQRb) 30 (25–36) 30 (25–36) 0.56
Literate (in English), n (%) 387 (28%) 432 (31%) 0.18
Income $30/month, n (%) 509 (36%) 503 (35%) 0.77
Median BMI, kg/m2 (IQR) 20.3 (18.8–22.0) 20.8 (19.1–22.9) 0.0001
Previous hospitalization (past 5 years), n (%) 525 (36%) 345 (24%) 0.0001
Tuberculosis (past 5 years), n (%) 135 (9%) 30 (2%) 0.0001
Chronic diarrhea at enrollment, n (%) 91 (6%) 28 (2%) 0.0001
Median hematocrit, % (IQR) 39 (35–44) 43 (39–46) 0.0001
Median ESR, mm/h (IQR) 65 (35–93) 25 (10–46) 0.0001
aChi-square test (dichotomous variables) and Wilcoxon rank-sum test (continuous variables) used.
bIQR, interquartile range.
FIG. 1. Algorithm for modified Kigali combined (MKC)
staging with number of HIV-infected participants from this
cohort in each stage (WHO, Lab, and MKC) at enrollment.
To demonstrate the flow of this algorithm, 390 participants
were staged as clinical (WHO*) stage 3 at enrollment. Of
these 390 participants, 230 participants were laboratory stage
A (normal hematocrit and ESR results) and 157 participants
were laboratory stage B (abnormal hematocrit or ESR re-
sults). The 230 participants with clinical stage 3 and labora-
tory stage A were classified as MKC stage 2 and the 157 par-
ticipants with clinical stage 3 and laboratory stage B were
classified as MKC stage 3. WHO*: clinical stage based on
WHO staging with modifications described in Appendix 1.
determined with the TRAx CD4 assay (T Cell Diagnostics,
Inc., Cambridge, MA).22
The primary endpoint was mortality. Kaplan–Meier sur-
vival methods were used to evaluate median survival. For
Kaplan–Meier analysis, survival time was censored on De-
cember 31, 2004 for all surviving active participants since
HAART became available after this date.15 Survival times
were stratified by MKC stage and compared by log-rank
tests. Cox proportional hazards regression was employed
(SAS version 9.1, SAS Institute, Cary, NC) to identify vari-
ables associated with mortality. Variables associated with
mortality in univariate analyses with a p-value 0.10 were
included in a multivariate Cox proportional hazards regres-
sion model. We included CD4 cell count results in a sepa-
rate multivariate Cox proportional hazards regression model
for the 213 participants with CD4 cell count results. In these
models the lowest risk stratification for mortality was used
as the reference against which the highest risk stratification
was compared.
Study procedures were approved by the University of
Zambia’s Research Ethics Committee in Lusaka, the Institu-
tional Review Boards of Emory University, the University of
Alabama at Birmingham, and the University of California at
San Francisco, and the Office of Protection from Research
Risks of the National Institutes of Health, Bethesda, MD.
Written informed consent was obtained from all study par-
ticipants and the human experimentation guidelines of all
respective institutions involved in conducting the study
were followed.
Results
We enrolled 1479 HIV-discordant couples (750 with an
HIV-infected female and 729 with an HIV-infected male)
with a combined 7305 person-years of follow-up. HIV-in-
fected participants (n  1479) had a median follow-up of 21
months [interquartile range (IQR) 11–41 months]. Among
HIV-infected participants over the 9-year study period, there
were 333 (23% of total HIV-infected participants) confirmed
deaths. A total of 442 (30%) HIV-infected participants were
still active in the cohort when follow-up was censored on
December 31, 2004. An additional 352 (24%) participants had
voluntarily withdrawn from the study, 184 (12%) had been
lost to follow-up, and 168 participants (11%) were dropped
from the overall study due to separation from or death of
their HIV-negative partner. Among HIV-negative partici-
pants who remained HIV negative during the study (n 
1204), there was a median follow-up of 20 months (IQR: 9–33)
and 32 (3%) confirmed deaths. Among HIV-negative partic-
ipants who seroconverted during the study (n  275), there
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FIG. 2. Survival among HIV-infected Zambian adults stratified by MKC stage (n  1479).
was a median follow-up of 26 HIV-infected months (IQR:
12–56) and 24 (9%) confirmed deaths.
All couples were in stable cohabiting relationships with
14% in a legal marriage and 86% in a common law union.
Overall baseline demographic features were similar among
the cohort of HIV-infected participants and their HIV-nega-
tive partners (Table 1). The median enrollment age was 30
years (IQR: 25–36) for both HIV-infected participants and
their HIV-negative partners. HIV-infected participants, how-
ever, were more likely to report previous hospitalizations, a
history of tuberculosis, and chronic diarrhea at study en-
rollment. HIV-infected participants also had lower baseline
median hematocrit and higher median ESR results. HIV-in-
fected women reported a mean of 3.2 previous pregnancies
and 100 (13%) of 750 HIV-infected women were pregnant at
the time of enrollment.
At enrollment, 895 (61%) HIV-infected participants had ei-
ther MKC stage 1 or 2 (Fig. 1). A total of 446 (30%) and 138
(9%) HIV-infected participants had MKC stage 3 and 4, re-
spectively. Women (n  480; 64%) were more likely than
men (n  415; 57%) to be MKC stage 1 or 2 (p  0.01). Men
(n  91; 13%) were more likely than women (n  47; 6%) to
be MKC stage 4 (p  0.01).
Overall, the median survival time for HIV-infected par-
ticipants was 7.7 years (IQR: 7.0–8.5). When stratified by
baseline MKC stage (Fig. 2), the median survival for HIV-in-
fected participants with MKC stage 1 or 2 disease was 8.5
years (IQR: 8.0–9.1). Participants with MKC stage 3 disease
had a median survival of 5.6 years (IQR: 4.7–7.7) (p  0.0001
compared to MKC 1 or 2 disease by log-rank test). Partici-
pants with MKC stage 4 disease had a median survival of
3.7 years (IQR: 2.2–4.8) (p  0.0001 compared to MKC 1 or 2
disease and MKC 3 disease by log-rank test). Survival rates
at 3 years were 85% (3%) with MKC stage 1 or 2 disease,
74% (6%) with MKC stage 3 disease, and 51% (11%) with
MKC stage 4 disease. In comparison, survival rates at 3 years
were 94% (2%) for HIV-negative participants and 92%
(4%) for participants who seroconverted during follow-up.
In univariate analysis MKC stage 3 and stage 4 disease,
clinical stage 3 and stage 4 disease, male gender, and age
35 years were predictive of mortality (Table 2). In multi-
variate analysis, MKC stage 4 disease (HR  3.7, 95% CI 
2.7–5.0) remained a significant predictor of mortality after
adjusting for clinical stage, gender, and age.
A total of 213 participants (14% of HIV-infected partici-
pants) had CD4 cell count testing performed in a cross-sec-
tional substudy. Participants with CD4 cell count results
were more likely to be male (p  0.03) and were more likely
(p  0.055) to have MKC 1 or 2 disease (141/213, 66%) com-
pared to participants who did not have CD4 cell count test-
ing (750/1266, 59%). The median CD4 cell count was 333
cells/l (IQR 229–461 cells/l) and 39 (18%) participants had
a CD4 cell count 200 cells/l. Among these participants
with 200 cells/ l, 23 had MKC stage 1 or 2 disease, 14 had
MKC stage 3 disease, and only 2 had MKC stage 4 disease.
Conversely, among participants with MKC stage 1 or 2 dis-
ease (n  141, 66% of the participants with CD4 cell count
results) 63 (45%) had a CD4 cell count 350 cells/l, 55
(39%) had a CD4 cell count from 201 to 349 cells/l, and
23 (16%) had a CD4 cell count 200 cells/l. In multivari-
ate analysis (Table 3) both MKC stage 4 disease (HR  2.8,
95% CI  1.2–6.4) and CD4 cell count 200 cells/ l (HR 
3.8, 95% CI  2.0–7.1) remained significant predictors of
mortality.
Discussion
In this prospective cohort study of HIV-discordant cou-
ples in Lusaka, Zambia, MKC staging was a powerful, low-
cost tool to predict risk for mortality in HIV-infected adults.
Overall, HIV-infected adults with MKC stage 4 disease had
a high rate of mortality after 3 years of follow-up compared
to HIV-infected participants with MKC stage 1 or 2 disease
who had a low rate of mortality. MKC staging also remained
an independent predictor of mortality even when control-
ling for clinical stage and CD4 cell count.
CD4 cell count and viral load testing are well established
tests3,7,23 that can identify HIV-infected individuals at high
risk for mortality, but access to these technologies in many
African countries can be limited (although it has increased
PETERS ET AL.922
TABLE 2. COX PROPORTIONAL HAZARD RATIOS (HR) FOR MORTALITY AMONG HIV-INFECTED ZAMBIAN PARTICIPANTS (N  1479)
n (%) Univariate HR (95% CI) p-value Multivariate HR (95% CI) p-value
MKC stage
1  2 895 (61%) Ref. .— — .—
3 446 (30%) 1.9 (1.5–2.4) 0.0001 2.0 (1.6–2.7) 0.0001
4 138 (9%) 3.8 (2.8–5.2) 0.0001 4.7 (2.8–7.9) 0.0001
Clinical stage
1  2 819 (56%) Ref. .— — .—
3 390 (26%) 1.5 (1.1–1.9) 0.0028 1.3 (1.0–1.7) 0.07
4 270 (18%) 2.5 (1.9–3.2%) 0.0001 0.8 (0.5–1.3) 0.44
Agea (years)
24 323 (22%) Ref. .— — .—
25–29 372 (25%) 1.3 (0.9–1.8) 0.1362 — .—
30–34 314 (21%) 1.2 (0.8–1.7) 0.3612 — .—
35 462 (32%) 2.1 (1.5–2.9) 0.0001 1.7 (1.4–2.2) 0.0001
Gender
Female 750 (51%) Ref. .— — .—
Male 729 (49%) 1.4 (1.1–1.7) 0.0026 1.1 (0.9–1.4) 0.27
aEight participants were missing age data.
markedly since 2004). WHO clinical staging is an equally im-
portant method to identify HIV-infected individuals at high
risk for mortality and provides information that is indepen-
dently predictive.9–13,24 WHO staging, however, can be ham-
pered in many resource-limited settings as the technology to
diagnose stage 4 opportunistic infections is often not avail-
able. Furthermore stage 4 symptoms, such as HIV wasting
syndrome (defined as weight loss 10% of body weight, plus
either unexplained chronic diarrhea or chronic weakness and
unexplained prolonged fever), can be prevalent even among
HIV-negative African adults.21
In our cohort MKC staging was a stronger predictor of
mortality than clinical staging alone. MKC staging incorpo-
rates objective measurements of wasting (BMI), anemia, and
inflammation (ESR), which have all been independently as-
sociated with HIV-related mortality.3,25–28 These measure-
ments are low cost and can be easily performed in a resource-
constrained clinical setting. The exact mechanism by which
a low BMI, anemia, and an elevated ESR contribute to HIV-
related mortality is unknown. Abnormalities in any of these
measurements may result from an opportunistic infection 
or may reflect advanced HIV infection. Regardless of the
mechanism, however, access to these low-cost measurements
could improve decisions on when to initiate antiretrovirals.
MKC staging also identified HIV-infected adults who
were at low risk for short-term (3 year) mortality. Although
the 3-year mortality rate with MKC stage 1 or 2 disease was
low, it was higher than the observed mortality of HIV-neg-
ative participants and HIV-infected participants with recent
HIV seroconversion. This difference in mortality rates is ex-
plained by the observation that 17% of HIV-infected partic-
ipants with MKC stage 1 or 2 disease had a CD4 cell count
200 cells/l. Therefore although HIV-infected participants
with MKC stage 1 or 2 have a high probability of 3-year sur-
vival, there is still a need to increase access to CD4 cell count
testing to identify individuals with mild clinical symptoms
but advanced disease.
A limitation of our study was that CD4 cell count data
were available for only a subset (14%) of participants. In this
subset, however, MKC staging remained an independent
predictor of mortality when controlling for CD4 cell count.
We would, therefore, recommend using MKC staging as an
adjuvant to CD4 cell count testing when available because
each test provides independent information on risk of mor-
tality. In situations where CD4 cell count testing is not avail-
able we would recommend using MKC staging as a primary
method to evaluate prognosis because it is a stronger pre-
dictor of mortality than clinical staging alone.
Another limitation of our study was a significant rate of
loss to follow-up, which could result in an underestimation
of mortality. We minimized underestimations of mortality,
however, by having a social worker visit the participant’s
home after a missed study visit. Missed visits due to hospi-
talization or illness were subsequently followed up by a clin-
ical officer and any deaths that occurred at home were in-
vestigated by a trained nurse who performed a verbal
autopsy with the surviving family members.
In conclusion, our study demonstrates the utility of in-
corporating ESR, hematocrit, and BMI with clinical staging.
The MKC staging system remains independently predictive
of mortality when controlling for either clinical stage or
CD4 cell count. MKC staging is therefore a powerful, low-
cost tool to identify HIV-infected adults at high risk for mor-
tality who require HAART.
Appendix 1
Modifications to the WHO clinical staging:
Modified clinical stage I: Same as WHO clinical stage I.
Modified clinical stage II: Same as WHO clinical stage II,
but body mass index between 19 kg/m2 and 21 kg/m2 is
substituted for weight loss.
Modified clinical stage III: Same as WHO clinical stage III,
but with the following changes: (1) body mass index of 19
kg/m2 or less is substituted for weight loss and (2) oral can-
didiasis and pulmonary tuberculosis are not included.
Modified clinical stage IV: Same as WHO clinical stage IV,
but with the following changes: (1) substitution of body mass
index of 19 kg/ m2 or less for weight loss, (2) addition of
chronic (1 month) oral or genital ulcer, and (3) addition of
oral candidiasis and pulmonary tuberculosis.
Laboratory results were stratified as either stage A (normal)
or stage B (an abnormal hematocrit or ESR result). For HIV-
infected Zambians in this cohort, an abnormal hematocrit was
defined as a result less than or equal to the sex-specific 25th
percentile (male: 38%, female: 34%) and an abnormal ESR
was defined as a result greater than or equal to the sex-spe-
cific 75th percentile (male: 82 mm/h, female: 100 mm/h).
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